news paper icon

Analyzed News

Biohaven's treatment for Lou Gehrig's disease fails to win FDA nod

Biohaven Pharmaceutical Holding Co Ltd said on Friday the U.S. health regulator failed to approve its treatment for amyotrophic lateral sclerosis, or Lou Gehrig's disease, sending its shares down nearly 6% in extended trading. [Source]

Publication Date:


Category: companyNews

Topics: disease, treatment, ltd said, holding, health

Source Link:

Related Articles